Using stem cells and iPS cells to discover new treatments for Parkinson's disease

Parkinsonism and Related Disorders

Volumn 18, Issue SUPPL. 1, 2012, Pages

  Cooper, Oliver ^a   Hallett, Penny ^a   Isacson, Ole ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cell therapy; Cell type specific vulnerability; Drug discovery; Individualized; Restorative

Indexed keywords

ALPHA SYNUCLEIN;

ARTICLE; CELL DIFFERENTIATION; CELL LINE; CELL MIGRATION; CELL PROLIFERATION; CELL THERAPY; CELL TYPE; DOPAMINERGIC NERVE CELL; EMBRYONIC STEM CELL; HUMAN; LEWY BODY; MESENCEPHALON; NERVE CELL; NERVE DEGENERATION; NEURAL STEM CELL; NONHUMAN; PARKINSON DISEASE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; STEM CELL; SUBVENTRICULAR ZONE;

EID: 84858627916     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/s1353-8020(11)70007-4     Document Type: Article

References (20)

1. Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Rehncrona S, et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci Transl Med 2010;2(38):38ra46.
2. Ma Y, Tang C, Chaly T, Greene P, Breeze R, Fahn S, et al. Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)F-FDOPA PET outcomes. J Nucl Med 2010;51(1):7-15.
3. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008;14(5):501-3.
4. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008;14(5):504-6.
5. Mendez I, Vinuela A, Astradsson A, Mukhida K, Hallett P, Robertson H, et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med 2008;14(5):507-9.
6. Cooper O, Astradsson A, Hallett P, Robertson H, Mendez I, Isacson O. Lack of functional relevance of isolated cell damage in transplants of Parkinson's disease patients. J Neurol 2009;256(Suppl 3):310-6.
7. Fallon J, Reid S, Kinyamu R, Opole I, Opole R, Baratta J, et al. In vivo induction of massive proliferation, directed migration, and differentiation of neural cells in the adult mammalian brain. Proc Natl Acad Sci U S A 2000;97(26):14686-91.
8. Cooper O, Isacson O. Intrastriatal transforming growth factor alpha delivery to a model of Parkinson's disease induces proliferation and migration of endogenous adult neural progenitor cells without differentiation into dopaminergic neurons. J Neurosci 2004;24(41):8924-31.
9. de Chevigny A, Cooper O, Vinuela A, Reske-Nielsen C, Lagace DC, Eisch AJ, et al. Fate mapping and lineage analyses demonstrate the production of a large number of striatal neuroblasts after transforming growth factor alpha and noggin striatal infusions into the dopamine-depleted striatum. Stem Cells 2008;26(9):2349-60.
10. Deleidi M, Cooper O, Hargus G, Levy A, Isacson O. Oct4-induced reprogramming is required for adult brain neural stem cell differentiation into midbrain dopaminergic neurons. PLoS One 2011;6(5):e19926.
11. Kim JB, Greber B, Arauzo-Bravo MJ, Meyer J, Park KI, Zaehres H, et al. Direct reprogramming of human neural stem cells by OCT4. Nature 2009;461(7264): 649-3.
12. Bjorklund LM, Sanchez-Pernaute R, Chung S, Andersson T, Chen IYC, McNaught KSP, et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation into a Parkinson rat model. Proc Natl Acad Sci U S A 2002;99(4):2344-9.
13. Hedlund E, Pruszak J, Ferree A, Vinuela A, Hong S, Isacson O, et al. Selection of embryonic stem cell-derived enhanced green fluorescent protein-positive dopamine neurons using the tyrosine hydroxylase promoter is confounded by reporter gene expression in immature cell populations. Stem Cells 2007;25(5):1126-35.
14. Wernig M, Zhao JP, Pruszak J, Hedlund E, Fu D, Soldner F, et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A 2008;105(15):5856-61.
15. Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009;136(5):964-77.
16. Hargus G, Cooper O, Deleidi M, Levy A, Lee K, Marlow E, et al. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci U S A 2010;107(36):15921-6.
17. Pruszak J, Ludwig W, Blak A, Alavian K, Isacson O. CD15, CD24, and CD29 define a surface biomarker code for neural lineage differentiation of stem cells. Stem Cells 2009;27(12):2928-40.
18. Cooper O, Hargus G, Deleidi M, Blak A, Osborn T, Marlow E, et al. Differentiation of human ES and Parkinson's disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid. Mol Cell Neurosci 2010;45(3):258-66.
19. Wider C, Wszolek ZK. Clinical genetics of Parkinson's disease and related disorders. Parkinsonism Relat Disord 2007;13(Suppl 3):S229-32.
20. Placantonakis DG, Tomishima MJ, Lafaille F, Desbordes SC, Jia F, Socci ND, et al. BAC transgenesis in human embryonic stem cells as a novel tool to define the human neural lineage. Stem Cells 2009;27(3):521-32.